• Title of article

    Clinical pharmacology and the use of articaine for local and regional anaesthesia

  • Author/Authors

    Tom B. Vree، نويسنده , , Mathieu J.M. Gielen، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 2005
  • Pages
    16
  • From page
    293
  • To page
    308
  • Abstract
    Quicker onset and shorter elimination time favours (±) articaine as a short-acting local anaesthetic for regional anaesthesia in day-case settings, e.g. arthroscopy (shoulder, knee), hand and foot surgery, and dentistry, because patients treated with articaine will be ‘drug free’ more quickly than those who receive other local anaesthetics. Articaine diffuses better through soft tissue and bone than other local anaesthetics. The concentration of articaine in the alveolus of a tooth in the upper jaw after extraction was about 100 times higher than that in systemic circulation. Articaine is metabolised via hydrolysis into articainic acid, 75% of which in turn is excreted as such and 25% in the glucuronidated form by the kidneys.The half-lives of elimination (t½α and t½β) of articaine are 0.6 and 2.5 hours, whereas the apparent half-life of the metabolite articainic acid is 2.5 hours. Intrinsic half-lives of articainic acid are: t½α 12 minutes, and t½β 64 minutes (1 hour). In dentistry, articaine is the drug of choice in the vast majority of literature. In other regional anaesthesia techniques (intravenous regional anaesthesia, epidural, spinal and plexus blocks) there are not enough data to prove that (±) articaine is safer and more effective than the short-acting local anaesthetics lidocaine, (±) prilocaine or (±) mepivacaine.
  • Keywords
    Pharmacokinetics , Articaine , Dentistry , articainic acid , articainic acid glucuronide , regional anaesthesia.
  • Journal title
    Best Practice and Research Clinical Anaesthesiology
  • Serial Year
    2005
  • Journal title
    Best Practice and Research Clinical Anaesthesiology
  • Record number

    465038